1,064 results
6-K
EX-99.4
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts … associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market
6-K
EX-99.1
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include … related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic
6-K
EX-99.2
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include … pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
is settling these cases, not because Sanofi believes the claims have any merit, but rather to avoid expenses and ongoing distraction of the litigation … million mainly related to redundancy plans announced during Q1 2024 and separation costs of the CHC business.
Other gains and losses, and litigation
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
)
Y924
2.m.
TEXT
Services rendered by affiliates
2.n.
TEXT
Litigation Expenses
2.o.
TEXT 4468
2.p.
3. Discontinued operations and applicable income
F-3ASR
9yhcb8lciy ghnah4
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
S-8
q0oifdghe2roql ad7w
4 Apr 24
Registration of securities for employees
8:45am
6-K
EX-99.1
ktcslb0bb4
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
6-K
EX-99.2
jxr9nu2kh908g0ugrzjt
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.5
qvo480bj4q7m82kb
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.4
fy3wymcc
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
o48fj1xos7xl ge
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
5tbyxlvog51an
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
o1v im2woktn
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
ffapn8mopaq 8ph
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
EX-99.1
x77he
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
EX-99.3
02uwo
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.2
yhbo tivtf
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.4
ye89m2u w6uzg1eecis
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.5
5u6 hk0eop7r7hyv
20 Dec 23
Current report (foreign)
10:39am